Revvity Beats Q4 Estimates, Raises 2026 Forecast

Revvity Reports Strong Q4 Earnings and Optimistic Outlook

Medical equipment manufacturer Revvity announced fourth-quarter results that significantly surpassed Wall Street expectations. The company reported an adjusted profit of $1.70 per share on sales of $772.1 million, beating estimates of $1.55 per share and $761.3 million in sales, respectively.

Market Conditions and Segment Performance

The life sciences sector is experiencing improved conditions in the pharmaceutical market, which helps offset subdued spending from academic institutions. Revvity's diagnostics unit was a key driver, posting 7% organic growth with revenue of $390.1 million. The life sciences unit recorded revenue of $382 million, slightly below estimates.

Upgraded Long-Term Financial Targets

Following the strong performance, Revvity issued an optimistic forecast for 2026. The company now expects annual sales between $2.96 billion and $2.99 billion and an adjusted profit per share of $5.35 to $5.45. Both projections are above current analyst consensus, signaling confidence in sustained growth.

Future Outlook

Revvity's positive forecast reflects continued strength in its diagnostics business, positioning the company for growth despite persistent weakness in academic research funding. This performance aligns with strong results from industry peers like Danaher and Thermo Fisher Scientific.

FAQ

Q: What were Revvity's key fourth-quarter results?
A: Revvity reported a Q4 adjusted profit of $1.70 per share and revenue of $772.1 million, both exceeding analyst expectations.

Q: What is Revvity's financial forecast for 2026?
A: The company projects 2026 revenue of $2.96 billion to $2.99 billion and adjusted EPS between $5.35 and $5.45.

Source: Investing.com